Autolus Therapeutics (AUTL) Status Update summary

FELIX study results and clinical insights

• Updated data from the pivotal FELIX study of obe-cel in adult relapsed/refractory B-cell ALL show 40% of responders remain in remission at a median 21.5 months follow-up, without subsequent transplant or other therapies.

• Both event-free survival (EFS) and overall survival (OS) curves suggest a potential for long-term plateau, mirroring positive pediatric CAR T-cell therapy outcomes.

• Consolidation with stem cell transplant after obe-cel did not improve EFS or OS; 80% of those transplanted relapsed or died, likely due to loss of CAR T-cell persistence post-conditioning.

• Ongoing CAR T-cell persistence is strongly associated with improved EFS, with loss of persistence increasing relapse or death risk by 2.7x.

• Patients with lower tumor burden at lymphodepletion had superior long-term outcomes, with EFS stabilizing around 70%.

Safety, patient population, and practice implications

• Obe-cel demonstrated a favorable safety profile, with only 2% experiencing high-grade cytokine release syndrome and 7% high-grade ICANS, lower than comparator therapies.

• The study included heavily pretreated adults (median age 47, median 2 prior therapies), with 44% having prior stem cell transplant and 42% prior blinatumomab exposure.

• Durable responses were observed even in high-risk patients, though lower disease burden at lymphodepletion correlated with better outcomes.

• The ease of administration and low toxicity profile make obe-cel suitable for older and comorbid patients, expanding access to CAR T therapy.

• Physicians are enthusiastic about obe-cel’s potential to become standard of care, with broad support across adult and pediatric sectors.

Regulatory, commercial, and future directions

• Regulatory review is ongoing in the US (PDUFA date: Nov 16) and Europe, with UK filing planned; commercial launch preparations are advanced, targeting 30-36 US centers at approval, expanding to 60 within a year.

• Manufacturing readiness is established with a new UK facility licensed for production.

• Further data updates are expected at the EHA meeting, including analyses on bridging therapy and CAR T persistence.

• Ongoing studies are evaluating obe-cel in additional indications and in autoimmune disease, with initial data expected by year-end.

• The company is pursuing NTAP reimbursement in the US and planning sequential launches in Europe, starting with Germany, France, and the UK.